140 results about "Retinal cell" patented technology

The invention relates to a retina nerve and blood vessel unit in-vitro three-culture model and a preparation method thereof, and belongs to the technical field of biology. The invention provides an in-vitro three-culture model of a retina nerve and blood vessel unit. The in-vitro three-culture model is obtained by carrying out in-vitro Transwell indirect co-culture on retina microvascular endothelial cells, retina ganglion cells and retina Muller cells. The in-vitro three-culture model of the retina nerve and blood vessel unit is based on a three-cell indirect co-culture method, retina microvascular endothelial cells, retina ganglion cells and retina Muller cells are simultaneously incorporated by utilizing Transwell, and the three cells are in indirect contact. The in-vitro three-culture model of the retina nerve and blood vessel unit can be used for more objectively simulating pathophysiological states of various cells of the retina nerve and blood vessel unit, so that common pathophysiological changes of mutual dependence and interaction of the three cells under in-vitro conditions can be observed.

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.

The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.

The invention relates to the technical field of light emitting diodes, and discloses a multiband LED epitaxial structure and a preparation method thereof, the epitaxial structure comprises a substrate, a buffer layer, an N-type semiconductor layer, a low temperature stress release layer, a multi-quantum well light emitting layer, an electron blocking layer and a P-type semiconductor layer, the multi-quantum well light-emitting layer comprises a first multi-quantum well layer, a second multi-quantum well layer, a third multi-quantum well layer and a fourth multi-quantum well layer which are sequentially stacked, and each multi-quantum well layer comprises an InGaN quantum well layer and a variable barrier height regulation barrier layer which are periodically and alternately stacked. The variable barrier height regulation barrier layer comprises five sub-layers which are sequentially stacked on the InGaN quantum well layer, lambda 1 > lambda 2 > lambda 3, and lambda 3 = lambda 4. The healthy full-spectrum white light LED light source with the high color rendering index can be generated, the short-wave blue light is small in proportion, damage to human eye omentum cells is small, and the light emitting efficiency is high.

The invention discloses a construction method and application of a Prpf6 gene mutation induced single dose insufficient RP mouse model, and belongs to the technical field of molecular biology and biomedicine. The mouse model constructed by using the method provides a convenient, reliable and economic means for researching the relationship between PRPF6 gene mutation and retinitis pigmentosa diseases and the pathogenesis of the PRPF6 gene mutation, and provides an effective research model capable of stably inheriting in the research on the aspects of RP pathogenesis, treatment methods, drug screening and the like. The animal model is subjected to transcriptome and a series of phenotype detection, wherein a transcriptome result shows that Prpf6 gene knockout mouse retina has occurred a certain degree of metabolic abnormality, electrophysiological detection, fundus examination and Hamp; e staining results show that the shapes and functions of the retinal cell layer and the retina of the mouse are damaged, and the disease phenotype of RP is met.

The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3):(1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state,(2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.

One aspect of the present disclosure is a composition for preventing or treating a retinal degenerative disease, capable of preventing or delaying retinal cell degeneration. The composition for preventing or treating a retinal degenerative disease, in one aspect, contains exosomes extracted from human-derived mesenchymal stem cells as an active ingredient.

The present invention provides a pharmaceutical composition for preventing or treating ophthalmic diseases, comprising a nuclear receptor subfamily 2 group F member 1 (NR2F1) inhibitor. The NR2F1 inhibitor of the present invention rejuvenates retinal cells by inhibiting the expression of the NR2F1 gene or the activity of the NR2F1 protein, and thus has the effects of reducing cellular senescence of retinal pigment epithelial cells and restoring visual function.

Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.

The invention provides application of sennoside A in a medicine for preventing and / or treating retina light injury, and belongs to the technical field of eye medicine manufacturing. The drug effect verification of the sennoside A is carried out by taking a retina photoinjury mouse model as an experimental subject, and the result shows that the sennoside A can improve the cytopathic morphology of an outer nuclear layer and an inner nuclear layer of a retina, reduce the apoptosis of retinal cells, reduce the oxidative stress level in a body and inflammatory response in the body and improve the oxidation resistance. Therefore, sennoside A has a good protection effect on retina photoinjury. Therefore, the invention provides an application of sennoside A in a medicine for preventing and / or treating retina light damage and / or a product for relieving a visual fatigue function.

The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.

The invention discloses Hangzhou white chrysanthemum-derived exosome-like nano-vesicles, a preparation method thereof and application of the nano-vesicles in treatment of optic nerve retinal degeneration diseases. In-vitro experiments show that the Hangzhou white chrysanthemum-derived exosome-like nano-vesicles provided by the invention can effectively inhibit glutamic acid-induced retinal cell oxidative stress and mitochondrial injury and improve the cell activity. In-vivo experiments show that the survival rate of ganglion cells in the retina of an NMDA injury model mouse can be remarkably improved by injecting the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle into a vitreous cavity, and the visual electrophysiological function of the NMDA injury model mouse can be improved. The invention provides a new thought and method for treatment of optic nerve retinal degeneration diseases, and has a wide application prospect. In addition, the preparation method of the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle provided by the invention is simple, and has the advantages of low cost, wide applicability, good safety, no animal-derived components and the like.

The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.

Compositions, nucleic acid molecules, and methods for inducing retinal regeneration and reprogramming Muller glial cells (MGs) into retinal ganglion cells in a subject are described. The development of retina ganglion cell (RGC) transcription factors Pou4f2 and Islet1 increases the MG neurogenesis capability induced by Ascl1. The combination of Ascl1, Pou4f2, and Islet1 stimulates the MG to produce bipolar cells and RGC-like neurons. Likewise, a transcription factor Onecut1, which is expressed in developing retinal cells but not expressed in MG, induces MG to produce RCG-like cells. Other transcription factors that can be used include Irx2, Irx5, Neurod2, Ebf1, and Tcf3. The MG-derived RGC can exhibit action potential in vivo, and exhibit chromatin characteristics similar to those of developing RGC.

We provide a 3-dimensional configuration of an electrode array for neural cell stimulation designed to leverage migration of retinal cells into voids in the subretinal space. Walls surrounding each pixel align the electric field vertically, matching the orientation of bipolar cells in the retina, and thereby reduce the stimulation threshold. These walls also decouple the field penetration depth from the pixel width, enabling a decrease of the pixel size down to cellular dimensions. Inner retinal cells migrate into the electrode cavities, which enables very efficient stimulation. Due to 1-dimensional alignment of electric field along the cavities, stimulation threshold current density does not increase significantly with the reduced pixel size, unlike the quadratic increase seen with planar arrays.

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.

The invention belongs to the technical field of seaweed functional products, and particularly relates to fucoidin as well as a preparation method and application thereof, in particular to application of the fucoidin in food and preparation of medicines for adjuvant treatment of age-related maculopathy. According to the invention, alginate lyase is adopted to carry out enzymolysis on seaweed, and the fucoidin with the molecular weight of 20-60 kDa is obtained after treatment of multi-stage alcohol precipitation, hydrogen peroxide degradation and membrane interception. Experimental results show that the fucoidin has the effect of repairing retinal cells, can effectively improve maculopathy, can be used for preparing related products for treating age-related macular degeneration, and provides safer natural material support for treatment of age-related macular degeneration.

Novel anti-C3 and anti-C5 antibodies capable of modulating complement activity by specifically binding to human complement factor C3, C3a, C3b, and / or C5 are provided. Also described herein are recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding an anti-C3 and / or anti-C5 antibody are provided. Also provided are methods of delivering the transgene to the retina and methods of treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration disorders by contacting retinal cells with the rAAV)

According to the extraction method of the boxthorn seed oil and the application of the boxthorn seed oil in preparation of the eye-protecting and eyesight-improving product, through compounding of the boxthorn seed oil, the olive oil and the zeaxanthin and innovation of the preparation process, the boxthorn seed oil, the olive oil and the zeaxanthin have a synergistic effect on the eye-protecting and eyesight-improving effects, and meanwhile the bioavailability of the boxthorn seed oil is improved. An extraction system of the eutectic solvent and the enzyme preparation can hydrolyze cell walls of the lycium barbarum seeds, a net structure composed of cellulose is destroyed, and oily components in the lycium barbarum seeds are promoted to be released. Meanwhile, the deep-eutectic solvent has a protective effect on enzyme, so that the enzyme preparation has better hydrolytic activity under proper extraction conditions. According to the method, the oil yield of the wolfberry seed oil and the content of related active ingredients are greatly improved. On the other hand, the olive oil can significantly improve the intake of the active ingredients in the lycium seed oil by retinal cells, and the bioavailability of the lycium seed oil is improved.

The present application relates to the technical field of biological medicine, and particularly relates to application of Crybb2 recombinant protein in treatment and / or prevention of diabetic retinopathy. The present application finds that the use of Crybb2 recombinant protein can improve the activity of müller cells, reduce the level of GFAP, restore the level of GS, reduce inflammation, reduce apoptosis of retinal cells and restore the structure and function of the retina. It can be used for treatment and / or prevention of diabetic retinopathy.

The utility model relates to the technical field of mobile phone screen architecture, and particularly discloses a high-definition eye-protection mobile phone screen architecture, which comprises an OLED (Organic Light Emitting Diode) display panel, a protection mechanism and a cover plate, the OLED display panel, the protection mechanism and the cover plate are mutually connected, the protection mechanism is positioned between the OLED display panel and the cover plate, the protection mechanism comprises an anti-blue-light layer, an anti-glare layer and a glass substrate, and the anti-blue-light layer is positioned on the glass substrate. According to the OLED display panel, the protection mechanism and the cover plate are arranged on the OLED display panel, the anti-blue-light layer of the protection mechanism can filter blue light and reduce the damage of the blue light emitted by the OLED display panel to eyes, and the anti-glare layer of the protection mechanism is used for protecting the eyes and reducing the glare of a screen, so that the screen can be seen clearly under strong light; meanwhile, a certain improvement effect on screen flash is achieved, the mobile phone screen is used for protecting eyes and facilitating use of a user under strong light, the mobile phone screen has the function of protecting the eyes, and the problem that blue light generated by an existing mobile phone screen damages retinal cells is solved.

The invention discloses a neural retina synaptic device for artificial vision and a preparation method thereof. The neural retina synaptic device includes: a substrate; the electrode consists of a gate electrode, a source electrode and a drain electrode and is formed on the substrate; the channel layer is formed by a zero-dimensional quantum dot / two-dimensional material heterojunction thin film, has enhanced response to optical signals, is formed on the substrate, is used for connecting the source electrode and the drain electrode to form an electrical path, and is far away from the gate electrode; and the gate dielectric layer is made of an electrolyte gate dielectric material and is connected with the channel and the gate electrode to form a double-electrode layer. The gate electrode receives an electric signal to simulate a synaptic front end, the channel layer receives an optical signal to simulate a retinal cell light sensor, the source electrode, the drain electrode and the channel layer complete information collection, processing and storage by reading voltage, and the electric synaptic front end is adjusted to obtain positive and negative light current response. The method is used for constructing a sensing, storage and calculation integrated visual neuromorphic sensing system.

Disclosed herein are synthetic cone-specific promoters. The promoters can be used in nucleic acids, vectors, or host cells to drive expression of a heterologous polypeptide or RNA in retinal cells, particularly cones.

Provided herein are compositions comprising peptides, pharmaceutical preparations thereof, and methods of using the same to prevent photoreceptor death and protect retinal cells (including but not limited to photoreceptors and retinal pigment epithelium) from Fas- or TRAIL-mediated apoptosis.

The present invention relates to a method for attenuating retinal cell damage and other neuronal cell damage outside the central nervous system associated with reduced supply of neurotrophin, i.e., nerve growth factor (NGF), induced by glaucoma and other forms of neurodegeneration by orally administering a therapeutically effective amount of an aqueous extract of spearmint to a subject.

Viral constructs and methods of their use in the treatment of diseases and disorders mediated by reduced ELP1 expression are provided. The viral constructs include a coding sequence for human ELP1 under control of a heterogenous promoter (such as a small nuclear RNA promoter), allowing for an increase in ELP1 protein expression in neuron cells of the central nervous system, including for instance retinal cells. Methods of using such viral constructs to protect neural cells, for instance by reducing death of retinal ganglion cells, are also provided.

The invention relates to the technical field of biological medicine, in particular to application of Crybb2 recombinant protein to treatment and / or prevention of diabetic retinopathy. The application finds that by using the Crybb2 recombinant protein, the muler cell activity can be improved, the GFAP level can be reduced, the GS level can be recovered, the inflammation can be alleviated, the apoptosis of retinal cells can be reduced, and the structure and function of the retina can be recovered. The compound can be used for treating and / or preventing diabetic retinopathy.

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1A (or a variant thereof) or Formula A, an amino acid sequence set forth in Table 1B (or a variant thereof) or Formula B, or an amino acid sequence set forth in Table 1C (or a variant thereof) or Formula C, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and / or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and / or AAV capsid polypeptides are provided.

The invention relates to the technical field of light-emitting diodes, and discloses an epitaxial structure of a multiband light-emitting diode and a preparation method thereof, the epitaxial structure comprises a substrate, a buffer layer, an N-type semiconductor layer, a low-temperature stress release layer, a multi-quantum well light-emitting layer, an electron blocking layer and a P-type semiconductor layer, the multi-quantum-well light-emitting layer comprises a first multi-quantum-well layer, a second multi-quantum-well layer, a third multi-quantum-well layer and a fourth multi-quantum-well layer which are sequentially stacked, and each multi-quantum-well layer comprises InGaN quantum well layers and variable barrier height regulation barrier layers which are periodically and alternately stacked. The variable barrier height regulation barrier layer comprises five sub-layers which are sequentially stacked on the InGaN quantum well layer, and the light-emitting wavelengths of the first multi-quantum well layer to the fourth multi-quantum well layer are in a decreasing trend along the growth direction. According to the invention, the healthy full-spectrum white light LED light source with high color rendering index can be generated, and the short-wave blue light is small in proportion and causes little damage to human eye omentum cells.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.